The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the results of a Phase II study combining linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma. Prof. Dimopoulos reports encouraging safety and efficacy, warranting further investigation of this combination. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this particular trial, a bispecific monoclonal antibody linvoseltamab was combined with anti-CD38 monoclonal antibodies daratumumab and isatuximab. So this was a Phase II study which included heavily pretreated patients. Most of them were triple-class refractory with multiple myeloma. And we saw that with a combination of linvoseltamab and either daratumumab or isatuximab we were able to induce responses, objective responses in more than 80% of the patients...
In this particular trial, a bispecific monoclonal antibody linvoseltamab was combined with anti-CD38 monoclonal antibodies daratumumab and isatuximab. So this was a Phase II study which included heavily pretreated patients. Most of them were triple-class refractory with multiple myeloma. And we saw that with a combination of linvoseltamab and either daratumumab or isatuximab we were able to induce responses, objective responses in more than 80% of the patients. Furthermore, those patients who were available for minimal residual disease, we saw that all of them became MRD negative. The tolerability of the combination was as expected and the infection rate was decreased with the preemptive use of intravenous immunoglobulin. Thus we believe that this is an active combination that is worthy of further investigation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
